Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 12/20 | 0.69 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.57 |
| ▸ | ESR1 | P03372 | 3/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.54 |
| ▸ | AR | P10275 | 2/20 | 0.54 |
| ▸ | SHBG | P04278 | 1/20 | 0.54 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7617295 | 0.93 | SRD5A1 (0.64) | CYP19A1SRD5A1ESR1ESR2AR | |
| SCHEMBL7617290 | 0.93 | SRD5A1 (0.64) | CYP19A1SRD5A1ESR1ESR2AR | |
| SCHEMBL10274354 | 0.83 | SRD5A1 (0.49) | CYP19A1SRD5A1AR | |
| SCHEMBL10274355 | 0.82 | CYP19A1 (0.66) | CYP19A1SHBGSERPINA6 | |
| SCHEMBL10273329 | 0.79 | CYP19A1 (0.46) | CYP19A1SRD5A1 | |
| SCHEMBL12423999 | 0.78 | SRD5A1 (0.58) | SRD5A1SHBGSERPINA6 | |
| SCHEMBL14185033 | 0.78 | SRD5A1 (0.58) | SRD5A1SHBGSERPINA6 | |
| SCHEMBL4421313 | 0.78 | SRD5A1 (0.58) | SRD5A1SHBGSERPINA6 | |
| SCHEMBL14359642 | 0.78 | SRD5A1 (0.58) | SRD5A1SHBGSERPINA6 | |
| SCHEMBL9318216 | 0.78 | SRD5A1 (0.61) | CYP19A1SRD5A1ESR1ESR2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2660241-A2 | C-17-HETEROARYL STEROIDAL COMPOUNDS AS INHIBITORS OF CYP11B, CYP17, AND/OR CYP21 | BioMarin Pharmaceutical Inc. (US) | 2013-11-06 | — | — | EP | disclosed |
| US-20130252930-A1 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (CA) | 2013-09-26 | — | — | US | disclosed |
| US-20130252930-A1 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (CA) | 2013-09-26 | — | — | US | disclosed |
| WO-2012083112-A2 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252930-A1 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | CYP4A11, HSD17B11, CYP21A2 | CYP19A1 10/4885SRD5A1 38/4885ESR1 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.